Management focus is on a strong balance sheet
20/11/23 -"After the fairly decent Q3 results and the guidance cut on costs, a mix of lower operating costs, higher interest income (again) and a lower tax rate have all driven an upgrade to our 2023 EPS ..."
Pages
56
Language
English
Published on
20/11/23
You may also be interested by these reports :
07/08/26
Genmab’s Q2 performance exceeded expectations. The blood cancer drug Darzalex demonstrated strong results, with other drugs also showing solid ...
05/08/26
The Q2 results exceeded expectations, aided by sustained strong uptake for the Wegovy pill (obesity). Consequently, the management upgraded its ...
04/08/26
BioNTech reported a disappointing quarter, with sales significantly below forecasts and operating losses exceeding expectations. Weaker Covid-19 ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...